What happened with IMCC today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
IM Cannabis Corp. supplies medical cannabis to pharmacies and patients, with Germany contributing most of its revenue and Israel providing the other main market. Medical cannabis accounts for nearly all sales. In Germany, subsidiary Adjupharm buys cannabis from outside suppliers and sells IMC-branded and licensed-brand products to pharmacies, directly or through distributors. Pharmacies dispense these products to patients with prescriptions.
In Israel, the company imports cannabis, has licensed contractors package it, and sells through local pharmacies and distributors. It also operates the Vironna and Pharm Yarok pharmacies, with online ordering and home delivery. Its earnings depend on the gap between selling prices and the costs of obtaining and supplying products. One unnamed major customer contributes a meaningful share of revenue.
The business relies on third-party growers and producers delivering suitable cannabis and on maintaining supply and distribution agreements. Imports, processing and sales require regulatory approvals and licences in both countries; German imported products can reach patients only through prescription dispensing at pharmacies. The company also needs external financing to support operations and is managing cash daily while seeking additional funding.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Aurora Cannabis and IM Cannabis both supply medical cannabis to German pharmacies, so German patient demand and competition from imports matter to both. Watch Aurora’s German pharmacy business for signs of the demand and competitive pressure facing IM Cannabis.
Tilray Brands, Inc. competes with IM Cannabis for German medical cannabis sales by supplying pharmacies serving patients with prescriptions. Its news about supplying those pharmacies is more relevant to this rivalry than its beverage or wellness businesses.
Canopy Growth Corporation competes with IM Cannabis for prescriptions and pharmacy sales by supplying medical cannabis to Germany. Watch its German medical cannabis business, rather than its Canadian adult-use sales, for changes in the competition facing IM Cannabis’s pharmacy distributor Adjupharm.
Cronos Group Inc. Common Share and IM Cannabis sell medical cannabis to the same Israeli patient market, putting them in direct competition for demand. Cronos’s Israeli cultivation, production and distribution business is the part to watch for competitive pressure on IM Cannabis’s pharmacy and home-delivery sales.
IM Cannabis relies on Sundial Growers Inc. (SNDL) for Canadian cannabis flower exported for sale to Israeli patients through licensed pharmacies. Watch SNDL’s Israel shipments and export permits: IM Cannabis says access to premium Canadian cannabis is a key determinant of its success in Israel.
Sundial Growers Inc. earningsSNDL
SNDL’s report and related disclosures can show whether Canadian cannabis flower exports continue to supply IM Cannabis’s business in Israel.
Look for any disclosure of Canadian flower shipments to Israel and whether export permits allow supply to continue. Ongoing shipments would support a steadier source of product for IM Cannabis’s Israeli pharmacies and delivery business; blocked permits or interrupted shipments would put product availability and sales at risk, even if patient demand holds.
Aurora Cannabis Inc. earningsACB
Aurora Cannabis’s report can show what German pharmacy demand and competition look like for IM Cannabis’s distributor, Adjupharm.
Read Aurora’s German medical-cannabis sales alongside any volume detail. If both rise, pharmacy demand looks active, but Adjupharm also faces a stronger rival for pharmacy and prescription business. If sales fall, demand may be weakening, or Aurora may have company-specific problems; that alone does not prove the whole market is shrinking.
IM Cannabis Corp. earningsThis company
IM Cannabis’s report will show whether sales growth is translating into a smaller operating loss.
Read quarterly revenue alongside the operating loss. Revenue rising as the loss narrows means sales are covering more of the costs of running the business. Revenue rising while the loss widens means costs are growing faster; falling revenue with a wider loss points to greater operating strain. The question is whether sales are making the business less loss-making.
